Atopic Dermatitis

Copyright © 2019 Thrive Atopic Dermatitis. All Rights Reserved. Website by Divigner.

Welcome to Thrive Atopic Dermatitis​

Explore the THRIVE Clinician Toolkit, a comprehensive resource center for healthcare providers caring for patients with AD. Discover an abundance of practice essentials, including clinical pearls on diagnosis and treatment plus strategies and resources for the multidisciplinary management of AD.

Clinical Toolkit

Welcome to the THRIVE Patient Toolkit, a knowledge hub for patients diagnosed with AD, also known as eczema. Explore frequently asked questions to better understand symptoms and triggers for AD, as well as strategies and resources to help improve skin-related quality of life.

Patient Toolkit

Atopic Dermatitis Thrive

The Atopic Dermatitis Thrive initiative includes online CME offerings for clinicians and patients. It is particularly relevant to patient care since we are hoping to empower learners with usable therapeutic strategies to improve clinical experiences with atopic dermatitis. Through participating in our online offerings and exploring the information on our smart device app, we aim for our participants to more effectively manage patients with AD, ensure their quality of life, and promote a faster return to normalcy in their everyday lives.

This activity is provided by Med Learning Group.
This activity is co-provided by Ultimate Medical Academy/Complete Conference Management (CCM).
Supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals, Inc.

Copyright © 2019 Thrive Atopic Dermatitis. All Rights Reserved. Website by Divigner.

AD Breaking News

Noticias de última hora de AD

Dupilumab has also shown efficacy against atopic dermatitis in children 6 months to 5 years of age. Specifically, it demonstrated significantly better 16-week efficacy vs placebo on the following measures:

  • Achieving clear/almost clear skin (28% vs 4%).
  • Improving disease severity (70% vs 20%).
  • Reaching at least 75% improvement in overall disease severity (53% vs 11%).
  • Improving itch (49% vs 2%).

The safety profile in these young patients was similar to older populations in dupilumab clinical trials

Reference: Regeneron, Sanofi report positive Dupixent data in children 6 months to 5 years with atopic dermatitis. December 13, 2021. Available at: https://seekingalpha.com/news/3779368-regeneron-sanofi-report-positive-dupixent-data-in-children-6-months-to-5-years-with-atopic-dermatitis

Dupilumab también ha demostrado eficacia contra la dermatitis atópica en niños de 6 meses a 5 años. Específicamente, demostró una eficacia significativamente mejor durante 16 semanas en comparación con el placebo en las siguientes medidas:

  • Lograr una piel clara / casi limpia (28% frente a 4%).
  • Mejora de la gravedad de la enfermedad (70% frente a 20%).
  • Alcanzar al menos un 75% de mejora en la gravedad general de la enfermedad (53% frente al 11%).
  • Mejora del picor (49% vs 2%).

El perfil de seguridad en estos pacientes jóvenes fue similar al de las poblaciones de mayor edad en los ensayos clínicos de dupilumab.

Referencia: Regeneron, Sanofi informan datos positivos de Dupixent en niños de 6 meses a 5 años con dermatitis atópica. 13 de diciembre de 2021. Disponible en: https://seekingalpha.com/news/3779368-regeneron-sanofi-report-positive-dupixent-data-in-children-6-months-to-5-years-with-atopic-dermatitis

Dupilumab has also shown efficacy against atopic dermatitis in children 6 months to 5 years of age. Specifically, it demonstrated significantly better 16-week efficacy vs placebo on the following measures:

  • Achieving clear/almost clear skin (28% vs 4%).
  • Improving disease severity (70% vs 20%).
  • Reaching at least 75% improvement in overall disease severity (53% vs 11%).
  • Improving itch (49% vs 2%).

The safety profile in these young patients was similar to older populations in dupilumab clinical trials

Reference: Regeneron, Sanofi report positive Dupixent data in children 6 months to 5 years with atopic dermatitis. December 13, 2021. Available at: https://seekingalpha.com/news/3779368-regeneron-sanofi-report-positive-dupixent-data-in-children-6-months-to-5-years-with-atopic-dermatitis